The Way Out From the Labyrinth of Anticancer Therapies for Patients with Breast Cancer: How Can We Improve Their Cardiac Safety and Quality of Life?

Author:

Rygiel Katarzyna1

Affiliation:

1. Department of Family Practice, Medical University of Silesia (SUM), 3 Maja St., 41-800, Zabrze, Poland

Abstract

Patients with Breast cancer (BC) often experience a spectrum of adverse, anticancer therapy-related symptoms, which deteriorate their quality of life (QoL). Therefore, effective strategies for BC are needed. Personalized medicine offers many therapeutic options (e.g., targeted therapies) that can be tailored to the individual needs of a given patient. This chapter aims to briefly present typical side effects of current anticancer treatments, which often reduce the QoL of patients with BC and survivors. In particular, it addresses pain (including chemotherapy (CHT)-induced peripheral neuropathy (PN) and lymphedema), depression, cognitive dysfunction, premature menopause, and CHT-induced menopause. It focuses on the adverse effects of the BC therapies, such as chemotherapy (CHT), immunotherapy (IT), and some targeted therapies. In addition, several issues related to cardiovascular toxicity induced by anticancer treatments and cardioprotective measures for women with BC are addressed. This chapter also touches on the recent advances in precision medicine and provides some future directions, aimed at fulfilling unmet needs of patients with BC. The described approaches may be helpful in planning personalized treatment, facilitating the patient’s tolerability of many available anticancer therapies, optimizing the medication selection, and improving the patient’s QoL.

Publisher

BENTHAM SCIENCE PUBLISHERS

Reference36 articles.

1. Lei S.; Zheng R.; Zhang S.; Wang S.; Chen R.; Sun K.; Zeng H.; Zhou J.; Wei W.; Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020. Cancer Commun 2021 ,41(11),1183-1194

2. Cardoso F.; Senkus E.; Costa A.; Papadopoulos E.; Aapro M.; André F.; Harbeck N.; Aguilar Lopez B.; Barrios C.H.; Bergh J.; Biganzoli L.; Boers-Doets C.B.; Cardoso M.J.; Carey L.A.; Cortés J.; Curigliano G.; Diéras V.; El Saghir N.S.; Eniu A.; Fallowfield L.; Francis P.A.; Gelmon K.; Johnston S.R.D.; Kaufman B.; Koppikar S.; Krop I.E.; Mayer M.; Nakigudde G.; Offersen B.V.; Ohno S.; Pagani O.; Paluch-Shimon S.; Penault-Llorca F.; Prat A.; Rugo H.S.; Sledge G.W.; Spence D.; Thomssen C.; Vorobiof D.A.; Xu B.; Norton L.; Winer E.P.; 4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol 2018 ,29(8),1634-1657

3. Gradishar W.J.; Moran M.S.; Abraham J.; Aft R.; Agnese D.; Allison K.H.; Anderson B.; Burstein H.J.; Chew H.; Dang C.; Elias A.D.; Giordano S.H.; Goetz M.P.; Goldstein L.J.; Hurvitz S.A.; Isakoff S.J.; Jankowitz R.C.; Javid S.H.; Krishnamurthy J.; Leitch M.; Lyons J.; Mortimer J.; Patel S.A.; Pierce L.J.; Rosenberger L.H.; Rugo H.S.; Sitapati A.; Smith K.L.; Smith M.L.; Soliman H.; Stringer-Reasor E.M.; Telli M.L.; Ward J.H.; Wisinski K.B.; Young J.S.; Burns J.; Kumar R.; Breast cancer, version 3.2022, nccn clinical practice guidelines in oncology. J Natl Compr Canc Netw 2022 ,20(6),691-722

4. Gegechkori N.; Haines L.; Lin J.J.; Long-term and latent side effects of specific cancer types. Med Clin North Am 2017 ,101(6),1053-1073

5. Collins F.S.; Varmus H.; A new initiative on precision medicine. N Engl J Med 2015 ,372(9),793-795

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3